Everything below concerns cjc-1295. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-10-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
== Synthesis == The process used to create DBNPA is acid-catalyzed bromination of 3-cyanoacetamide. Polyethylene glycol is often used as the solvent due to its ability to dissolve both reactants and products effectively. Next, the bromination step is initiated by introducing bromine (Br2) or an alternative brominating agent, such as sodium bromide (NaBr) with an oxidant. DBNPA is formed as a result of an electrophilic bromination reaction at the α-carbon of 3-cyanoacetamide. Isolation and purification of DBNPA are carried out after bromination. The reaction mixture is neutralized, and the product is extracted and purified. The next step is drying, which yields DBNPA in its stable crystalline form. Usually, the reaction temperature is kept between 10 and 20 °C to minimize unintended side reactions. The concentration of bromine is carefully controlled, because an excess can lead to the formation of undesired byproducts that reduces the overall yield. The stability of DBNPA depends on the storage conditions. Due to its incompatibility with metals, DBNPA should be stored in non-metal containers. It must also be stored away from UV exposure, as this can degrade DBNPA.
Someone with a good memory of the conversation once told me how Lord Carrington, then one of the "mediators" of the incipient post-Yugoslavia war, came to the conclusion that Slobodan Milosevic was a highly dangerous man. Well-disposed toward Serbia (as the British establishment has always been), Carrington told the late dictator that he understood Serb concerns about significant Serbian minorities in Bosnia and Croatia. But why did Milosevic also insist on exclusive control over Kosovo, where the Albanian population was approximately 90 percent? "That," replied Milosevic coldly, "is for historical reasons." It's a shame, in retrospect, that it took us so long to diagnose the pathology of Serbia's combination of arrogance and self-pity, in which what is theirs is theirs and what is anybody else's is negotiable. After the war, Hitchens supported Kosovo's independence and criticized the burning of the US Embassy in Belgrade as a response to it:
== History == Heparin was discovered by Jay McLean and William Henry Howell in 1916, although it did not enter clinical trials until 1935. It was originally isolated from dog liver cells, hence its name (ἧπαρ hēpar is Greek for 'liver'; hepar + -in). McLean was a second-year medical student at Johns Hopkins University, and was working under the guidance of Howell investigating pro-coagulant preparations when he isolated a fat-soluble phosphatide anticoagulant in canine liver tissue. In 1918, Howell coined the term 'heparin' for this type of fat-soluble anticoagulant. In the early 1920s, Howell isolated a water-soluble polysaccharide anticoagulant, which he also termed 'heparin', although it was different from the previously discovered phosphatide preparations. McLean's work as a surgeon probably changed the focus of the Howell group to look for anticoagulants, which eventually led to the polysaccharide discovery. It had at first been accepted that it was Howell who discovered heparin. However, in the 1940s, Jay McLean became unhappy that he had not received appropriate recognition for what he saw as his discovery. Though relatively discreet about his claim and not wanting to upset his former chief, he gave lectures and wrote letters claiming that the discovery was his. This gradually became accepted as fact, and indeed after he died in 1959, his obituary credited him as being the true discoverer of heparin.
Sources: en.wikipedia.org
On May 26, 2016, Green Berets supported about 80 soldiers of the Afghan 3rd Special Operations Battalion whose mission was to clear insurgents from Elbak, Kandahar province. The goal was to clear the road from Kandahar through Elbak to Tarin Kowt and allow an 800-man Afghan army convoy to deliver troops and supplies to Tarin Kowt. Green Berets called in three airstrikes by U.S. drones on Taliban insurgents near the landing zone, killing seven and wounding others. The mission had mixed results. The Taliban reoccupied the area and the convoy barely made any progress, however the operation interrupted the Taliban's nightly routine of bomb-planting. A week later, the Afghan commandos removed 18 booby-trap bombs from the road and made their way slowly through Elbak and further north. On August 23, a US soldier from A Company, 3rd battalion, 1st SFG, was killed by an IED while another was wounded along with six Afghans during a foot patrol near Lashkar Gah, Helmand Province. On October 4, 2016, a US soldier from B Company, 2nd Battalion, 10th SFG was killed by a roadside bomb blast in Achin, Nangarhar province. He was on a patrol with Afghan forces during an operation against ISIL-KP militants. This marked the first time a U.S. serviceman was killed in combat against IS militants in the country. On October 17, DEA agents, supported by a US Army Green Beret A-team and Afghan counter-narcotic units conducted a warranted search in a remote village in Farah province.
The neck of the emu is pale blue and shows through its sparse feathers. They have grey-brown plumage of shaggy appearance; the shafts and the tips of the feathers are black. Solar radiation is absorbed by the tips, and the inner plumage insulates the skin. This prevents the birds from overheating, allowing them to be active during the heat of the day. A unique feature of the emu feather is the double rachis emerging from a single shaft. Both of the rachis have the same length, and the texture is variable; the area near the skin is rather furry, but the more distant ends resemble grass. The sexes are similar in appearance, although the male's penis can become visible when he urinates and defecates. The plumage varies in colour due to environmental factors, giving the bird a natural camouflage. Feathers of emus in more arid areas with red soils have a rufous tint while birds residing in damp conditions are generally darker in hue. The juvenile plumage develops at about three months and is blackish finely barred with brown, with the head and neck being especially dark. The facial feathers gradually thin to expose the bluish skin. The adult plumage has developed by about fifteen months. The eyes of an emu are protected by nictitating membranes. These are translucent, secondary eyelids that move horizontally from the inside edge of the eye to the outside edge. They function as visors to protect the eyes from the dust that is prevalent in windy arid regions. Emus have a tracheal pouch, which becomes more prominent during the mating season.
== Origin/development == The sulcular epithelium originates developmentally during tooth eruption when the reduced enamel epithelium derived from the enamel organ fuses with the oral epithelium to form a continuous epithelial lining around the tooth. The junctional epithelium is attached coronally to the sulcular epithelium which is thicker. At the bottom of the sulcus is the junctional epithelium in which the development starts with the reduced enamel epithelium the protective layer of epithelial tissue that covers the enamel before the eruption of the tooth forming a seal.The rest of the part separating the junctional epithelium with the oral epithelium at the free gingival margin is covered by the sulcular epithelium. Gingival epithelium complex covers the alveolar bone to the neck of the tooth and the sulcular epithelium is a component or part of this complex which helps in the preservation of periodontal health. The sulcular epithelium is described as stratified but non-keratinized unlike the attached gingival epithelium which is keratinized.The sulcular epithelium expresses a characteristic cytokeratin pattern in particular keratins K4 and K13.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.